# IQVIA Holdings Inc. – Consensus ‘buy’ rating and 5.4% Upside Potential

- Link: https://www.directorstalkinterviews.com/iqvia-holdings-inc.consensus-buy-rating-and-5.4-upside-potential/4121134783
- Published: 2023-12-01T12:17:43+00:00
- Author: Charlotte Edwards

**IQVIA Holdings Inc.** with ticker code (IQV) now have 19 confirmed analysts covering
the stock with the consensus suggesting a rating of ‘buy’. The target price High/
Low ranges between $265.00 and $190.00 calculating the average target price we see
$225.37. Given that the stocks previous close was at $213.81 this would imply there
is now a potential upside of 5.4%. There is a 50 day moving average of $196.97 while
the 200 day moving average is $205.65. The company has a market capitalization of
39.07B. The current share price for the company is: $214.10 USD

 The potential market cap would be $41,185,812,880 based on the market consensus.

The company has a dividend yield of 2.93%. Other points of data to note are a P/
E ratio of 35.98, revenue per share of $80.44 and a 4.9% return on assets.

IQVIA Holdings Inc. is a global provider of advanced analytics, technology solutions
and clinical research services to the life sciences industry. The Company operates
through three segments: Technology & Analytics Solutions, Research & Development
Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions
segment provides critical information, technology solutions and real-world insights
and services to the Company’s life science clients. The Research & Development Solutions
segment primarily serves biopharmaceutical customers, providing outsourced clinical
research and clinical trial related services. The Contract Sales & Medical Solutions
segment provides health care provider, including contract sales and patient engagement
services to both biopharmaceutical clients and the broader healthcare market. The
Company protects individual patient privacy. The Company conducts business in more
than 100 countries.

Share on: